Alzheimer's Disease Trial, Recruiting NCT06534658 Sponsor: Ruijin Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06534658
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 50 and 85 years old (male or female)
  • You have been diagnosed with dementia or mild cognitive impairment (MCI)
  • Your scores on standard memory and thinking tests fall within a specific range (MMSE score of 15–28 and CDR score of 1 or below — confirm with trial site if unsure what your scores are)
  • You and your family have been fully informed about the trial and are willing to sign a consent form

Who may not be able to join:

  • You have another brain or nervous system condition that could affect brain function, such as depression, a brain tumor, Parkinson's disease, epilepsy, multiple sclerosis, a history of brain injury, or similar conditions
  • You have another illness in your body that could affect memory or thinking, such as liver, kidney, or thyroid problems, severe anemia, vitamin B12 or folic acid deficiency, syphilis, HIV infection, or issues with alcohol or drug use
  • You have a condition that makes it very difficult or impossible for you to take part in memory and thinking tests
  • You are unable to have an MRI scan (for example, due to having certain metal implants or a pacemaker — confirm with trial site)
  • You have an intellectual disability or a mental developmental condition
  • You are unwilling to have a blood sample taken
  • You are unwilling to sign the consent form agreeing to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gang Wang, PhD. MD., RenJi Hospital

Phone: 18221457023

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
30 July 2020
Est. completion
30 July 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The change of incidence of cognitive impairment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov